Article
Resistance to Imatinib: Mechanisms and Management
1 Nov 2005
Abstract excerpt
Imatinib, a specific small molecule inhibitor of the Abl kinase, has become the standard drug therapy for chronic myelogenous leukemia in all phases. More than 80% of newly diagnosed patients with chronic phase attain a complete cytogenetic response (CCR). Although remissions in patients with early disease are generally durable, acquired resistance after an initial response is common in advanced disease....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.